Načítá se...
Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic skin disease characterized by inflammatory lesions that flare unpredictably. The impact of weekly adalimumab (ADAew) on HS flare is not well‐characterized. OBJECTIVE: To evaluate the impact of disease flare on health‐related quality of life (HRQ...
Uloženo v:
| Vydáno v: | J Eur Acad Dermatol Venereol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7318582/ https://ncbi.nlm.nih.gov/pubmed/31630445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.16023 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|